Zobrazeno 11 - 20
of 53
pro vyhledávání: ''
Publikováno v:
Journal of Clinical Oncology. 34:e12501-e12501
e12501Background: This study investigated whether mircoRNA profile and miR-3646 regulated sensitivity of breast cancer cells to Docetaxel (Doc). Methods: Doc-resistant MDA-MB-231 breast cancer cell line (MDA-MB-231/Doc) was successfully established i
Autor:
Norma O'Donovan, John Crown, Richard S. Finn, Michael J. Duffy, Dennis J. Slamon, Maeve Mullooly, Neil A. O'Brien, Dylan Conklin, Patricia M. McGowan
Publikováno v:
Journal of Clinical Oncology. 33:1099-1099
1099 Background: An urgent problem in breast cancer treatment is the identification and validation of a targeted therapy for triple-negative breast cancer (TNBC), ie, breast cancer negative for ER, PR and HER2. Neratinib is a low molecular weight irr
Autor:
Yasumasa Niwa, Susumu Hijioka, Nobumasa Mizuno, Makoto Ishihara, Kei Muro, Kenji Yamao, Tsutomu Tanaka, Kazuo Hara, Hiroshi Imaoka, Mitsuyoshi Hashimoto, Masahiro Tajika, Yasushi Yatabe
Publikováno v:
Journal of Clinical Oncology. 33:48-48
48 Background: Accurate assessment of human epidermal growth factor receptor (HER) 2 is essential for patients with gastric cancer (GC) who may benefit from therapies targeting this surface receptor such as trastuzumab. The extracellular domain (ECD)
Autor:
Jamie Riches, David H. Ilson, Tooba Imtiaz, Efsevia Vakiani, Marinela Capanu, David P. Kelsen, Michael F. Berger, Yelena Y. Janjigian, Geoffrey Y. Ku, Joanne F. Chou
Publikováno v:
Journal of Clinical Oncology. 33:63-63
63 Background: Trastuzumab-based therapy is the standard therapeutic approach for patients with metastatic HER2+ esophagogastric (EG) tumors. While trastuzumab prolongs survival in this population, responses are rarely complete and resistance invaria
Autor:
Catherine E. Ellis, Michael F. Press, Tobias Grob, Carmen P. Arenas-Elliott, Angela Santiago, Roberta Guzman, Ivonne Villalobos, Robert C. Gagnon, Andreas H. Marx
Publikováno v:
Journal of Clinical Oncology. 32:4072-4072
4072^ Background: Patient inclusion to the primary efficacy population of TRIO-013/LOGiC trial of lapatinib in combination with chemotherapy in advanced HER2-positive UGI adenocarcinomas required e...
Publikováno v:
Journal of Clinical Oncology. 28:1809-1810
Breast cancer is a heterogeneous disease that is currently being classified into at least four main classes: basal-like, which is primarily progesterone receptor (PR) negative, estrogen receptor (ER) negative, and HER2 negative (ie, triple negative);
Publikováno v:
Journal of Clinical Oncology. 31:97-97
97 Background: Hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-positive tumors generally cluster within the luminal/HER2 subset; whereas HR-negative/HER2-positive tumors reside in HER2-enriched subset. We investigated w
Autor:
Edith A. Perez, Steven M. Butler, Nancy E. Davidson, Yan W. Asmann, Farid Jamshidian, Steven Shak, Karla V. Ballman, E. Aubrey Thompson, Peter A. Kaufman, Diana B. Cherbavaz, Frederick L. Baehner, Julie Gralow, Amylou C. Dueck
Publikováno v:
Journal of Clinical Oncology. 31:520-520
520 Background: There is considerable interest in developing HER2 testing criteria for adjuvant H. We used the 21-gene assay to examine the relationship of HER2 mRNA to benefit from H. Methods: N9831 compared adjuvant chemotherapy AC-T to concurrent
Autor:
J Miles, Tri Tran, Joanne E. Mortimer, Jinha Mark Park, David Colcher, James R. Bading, Andrew Raubitschek, Mary Carroll, Kofi Poku
Publikováno v:
Journal of Clinical Oncology. 31:TPS11121-TPS11121
TPS11121 Background: We have developed 64Cu-DOTA-trastuzumab for PET imaging of HER2-positive breast cancer. We have determined that administering trastuzumab (45 mg) prior to 64Cu-DOTA-trastuzumab sharply reduces liver uptake of the radiotracer. We
Autor:
Hiroshi Saeki, Koji Ando, Yoshihiko Maehara, Hajime Ohtsu, Yasue Kimura, Masaru Morita, Eiji Oki, Satoshi Ida, Hiroyuki Kawano, Tetsuya Kusumoto
Publikováno v:
Journal of Clinical Oncology. 31:106-106
106 Background: The Trastuzumab for Gastric Cancer (ToGA) study is the first international trial to include Japanese patients with human epidermal growth factor 2 (HER2)-positive advanced or recurrent gastric or gastroesophageal junction cancer, whic